We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
+1.75%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$419M
AUM Growth
-$93.5M
(-18%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-33.49%
Top 10 Holdings %
Top 10 Hldgs %
52.05%
Holding
63
New
14
Increased
15
Reduced
10
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$99.3M |
| 2 |
UnitedHealth
UNH
|
+$17.6M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$8.23M |
| 4 |
Becton Dickinson
BDX
|
+$6.29M |
| 5 |
HCA Healthcare
HCA
|
+$6.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$13.5M |
| 2 |
Universal Health Services
UHS
|
+$11.4M |
| 3 |
Zimmer Biomet
ZBH
|
+$9.65M |
| 4 |
Waters Corp
WAT
|
+$7.83M |
| 5 |
Biogen
BIIB
|
+$6.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.68% |
| 2 | Energy | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Qiagen
QGEN
$8.88B
| – | – |
-42,437
| Closed | -$2.18M |
|
52
Sana Biotechnology
SANA
$1.13B
| – | – |
-63,446
| Closed | -$1.25M |
|
53
Sanofi
SNY
$105B
| – | – |
-60,000
| Closed | -$3.16M |
|
54
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
| – | – |
-5,000
| Closed | -$214M |
|
55
Sarepta Therapeutics
SRPT
$1.94B
| – | – |
-25,000
| Closed | -$1.94M |
|
|
56
Universal Health Services
UHS
$10.2B
| – | – |
-75,000
| Closed | -$11.4M |
|
|
57
Waters Corp
WAT
$40.9B
| – | – |
-20,000
| Closed | -$7.83M |
|
|
58
State Street SPDR S&P Biotech ETF
XBI
$10.5B
| – | – |
-100,000
| Closed | -$13.5M |
|
|
59
Zimmer Biomet
ZBH
$18.7B
| – | – |
-61,800
| Closed | -$9.65M |
|
|
MRTX
60
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-15,000
| Closed | -$2.42M |
|
|
EAR
61
DELISTED
Eargo, Inc. Common Stock
EAR
| – | – |
-1,089
| Closed | -$870K |
|
|
TPTX
62
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| – | – |
-30,000
| Closed | -$2.34M |
|
|
HRC
63
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| – | – |
-35,000
| Closed | -$3.98M |
|
Similar funds
AFP
PCGDR
ACM
9C
STFP
ADEF
AC
CIP
Sivik Global Healthcare's Q3 2021 Portfolio in Review
As of Q3 2021, Sivik Global Healthcare held 63 positions worth $419M, down 18% from $512M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Sivik Global Healthcare withdrew a net $140M in Q3 2021, closing 20 positions and reducing 10 holdings. Its most notable exit was State Street SPDR S&P Biotech ETF, an estimated $13.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 55% a quarter earlier, followed by Energy.
Against the trend, Sivik Global Healthcare opened a new position in Regeneron Pharmaceuticals worth $5.79M.
- Sivik Global Healthcare's largest Q3 2021 buy was Regeneron Pharmaceuticals: 160,000 shares worth $5.79M.
- Sivik Global Healthcare added most to UnitedHealth in Q3 2021, an estimated $17.6M increase.
- Sivik Global Healthcare's biggest Q3 2021 reduction was Humana, cutting an estimated $5.31M.
- Sivik Global Healthcare fully exited State Street SPDR S&P Biotech ETF in Q3 2021, selling an estimated $13.5M.
- Sivik Global Healthcare's ten largest holdings make up 52% of its $419M portfolio in Q3 2021.
- Sivik Global Healthcare opened 14 new positions and closed 20 in Q3 2021.
- Sivik Global Healthcare's portfolio value fell 18% quarter-over-quarter to $419M.
Based on Sivik Global Healthcare's 13F filing for Q3 2021, filed 12 Nov 2021.